PE20071116A1 - Compuestos de heteroarilo biciclicos como inhibidores de pde10 - Google Patents

Compuestos de heteroarilo biciclicos como inhibidores de pde10

Info

Publication number
PE20071116A1
PE20071116A1 PE2007000001A PE2007000001A PE20071116A1 PE 20071116 A1 PE20071116 A1 PE 20071116A1 PE 2007000001 A PE2007000001 A PE 2007000001A PE 2007000001 A PE2007000001 A PE 2007000001A PE 20071116 A1 PE20071116 A1 PE 20071116A1
Authority
PE
Peru
Prior art keywords
alkyl
bicycle
heteroaryl
benzoimidazole
pyridin
Prior art date
Application number
PE2007000001A
Other languages
English (en)
Inventor
Christopher John Helal
Patrick Robert Verhoest
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20071116A1 publication Critical patent/PE20071116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROARILO BICICLICO DE FORMULA (I), DONDE HET1 SE SELECCIONA DE HETEROARILO MONOCICLICO Y UN HETEROARILO BICICLICO, DONDE DICHO HET1 ESTA OPCIONALMENTE SUSTITUIDO CON POR LO MENOS UN R4; HET2 ES UN HETEROARILO MONOCICLICO OPCIONALMENTE SUSTITUIDO CON R5; HET3 ES UN HETEROARILO BICICLICO DE 8 O 9 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R6; R1 ES HALOGENO, OH, CIANO, ALQUILO C1-C8, ENTRE OTROS; B1 Y B2 SON CARBONO O NITROGENO; B3 ES CARBONO; B4 ES NITROGENO; X Y X1 SON OXIGENO, AZUFRE O C(R2)2; R4 ES H, ALQUILO C1-C8, CIANO, OH, ENTRE OTROS; R5 ES HALOGENO, OH, ALQUENILO C2-C8, ENTRE OTROS; R6 ES ALQUILO C1-C8, ALQUENILO C2-C8, OH, ENTRE OTROS; R2 ES ALQUILO C1-C8, H, ALQUENILO C2-C8, ENTRE OTROS; p ES 0, 1 O 2. SON COMPUESTOS PREFERIDOS: 1-METIL-2-[4-(4-PIRIDIN-4-IL-1H-PIRAZOL-3-IL)-FENOXIMETIL]-1H-BENZOIMIDAZOL, 2-[4-(1-ETIL-4-PIRIDIN-4-IL-1H-PIRAZOL-3-IL)-FENOXIMETIL]-1-METIL-1H-BENZOIMIDAZOL, 1-{3-[4-(1-METIL-1H-BENZOIMIDAZOL-2-IL-METOXI)-FENIL]-4-PIRIDIN-4-IL-PIRAZOL-1-IL}-PROPAN-2-OL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA (PDE), PREFERIBLEMENTE PDE-10 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS NEURODEGENERATIVOS, PSIQUIATRICOS, ENTRE OTROS
PE2007000001A 2006-01-05 2007-01-03 Compuestos de heteroarilo biciclicos como inhibidores de pde10 PE20071116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75645006P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
PE20071116A1 true PE20071116A1 (es) 2007-11-17

Family

ID=38131538

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000001A PE20071116A1 (es) 2006-01-05 2007-01-03 Compuestos de heteroarilo biciclicos como inhibidores de pde10

Country Status (10)

Country Link
US (1) US20070155779A1 (es)
EP (1) EP1979343A2 (es)
JP (1) JP2009522346A (es)
AR (1) AR058919A1 (es)
CA (1) CA2636264A1 (es)
NL (1) NL2000397C2 (es)
PE (1) PE20071116A1 (es)
TW (1) TW200736246A (es)
UY (1) UY30080A1 (es)
WO (1) WO2007077490A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
MX2011000175A (es) 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
RU2506260C2 (ru) * 2008-06-25 2014-02-10 Энвиво Фармасьютикалз, Инк. 1,2-дизамещенные гетероциклические соединения
WO2010019861A1 (en) * 2008-08-15 2010-02-18 University Of Louisville Research Foundation, Inc. Compounds, their syntheses, and their uses
TW201030001A (en) * 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
US8637500B2 (en) 2008-12-17 2014-01-28 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
KR101662699B1 (ko) * 2009-05-07 2016-10-05 포럼 파마슈티칼즈 인크. 페녹시메틸 헤테로고리 화합물
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
US8349830B2 (en) 2009-10-30 2013-01-08 Merck Sharp & Dohme Aryl aminopyridine PDE10 inhibitors
JP5778164B2 (ja) * 2009-10-30 2015-09-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 放射標識ｐｄｅ１０リガンド
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
MX351368B (es) 2010-05-26 2017-10-12 Sunovion Pharmaceuticals Inc Compuestos heteroarilo y metodos para utilizarlos.
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
JP5973990B2 (ja) * 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
WO2012162213A1 (en) * 2011-05-24 2012-11-29 Merck Sharp & Dohme Corp. Aryloxymethyl cyclopropane derivatives as pde10 inhibitors
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
ES2572527T3 (es) * 2011-08-25 2016-06-01 Merck Sharp & Dohme Corp. Inhibidores de PDE10 de pirimidina
SG11201400759RA (en) * 2011-09-19 2014-07-30 Hoffmann La Roche Triazolopyridine compounds as pde10a inhibitors
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
MX2014005705A (es) 2011-11-09 2014-09-04 Abbvie Deutschland Carboxamidas heterociclicas utiles como inhibidores de fosfodiesterasa del tipo 10a.
US9138494B2 (en) * 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
US9309232B2 (en) * 2012-04-24 2016-04-12 Board Of Trustees Of Northern Illinois University Synthesis of novel inhibitors of isoprenoid biosynthesis
EA201491967A1 (ru) 2012-04-26 2015-03-31 Бристол-Майерс Сквибб Компани Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
KR20150003766A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
DK3243826T3 (da) 2012-04-26 2020-02-03 Bristol Myers Squibb Co Imidazothiadiazol-og imidazopyrazinderivater som proteaseaktiverede receptor 4- (par4) hæmmere til behandling af blodpladeaggregation
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
RU2015114331A (ru) 2012-09-17 2016-11-10 Эббви Дойчланд Гмбх Унд Ко. Кг Новые соединения в качестве ингибиторов фосфодиэстеразы типа 10а
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9790203B2 (en) * 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
BR112015021701A2 (pt) 2013-03-14 2017-07-18 Abbvie Deutschland novos compostos inibidores da fosfoestearase tipo 10a
US9464076B2 (en) 2013-03-15 2016-10-11 Daiichi Sankyo Company, Limited Benzothiophene derivative
SI3055315T1 (sl) * 2013-10-11 2018-11-30 F. Hoffmann-La Roche Ag Tiazolopirimidinoni kot modulatorji aktivnosti receptorjev NMDA
CN107531696B (zh) 2015-04-15 2021-03-16 豪夫迈·罗氏有限公司 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
US20210379061A1 (en) 2018-09-28 2021-12-09 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
GB202110990D0 (en) * 2021-07-30 2021-09-15 Benevolentai Cambridge Ltd Organic compound and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
US5843958A (en) * 1996-11-27 1998-12-01 Ortho Pharmaceutical Corporation Arylpyrazoles as leukotriene inhibitors
MXPA06014236A (es) * 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
SI1841757T1 (sl) * 2005-01-07 2010-09-30 Pfizer Prod Inc Heteroaromatske kinolinske spojine in njihova uporaba kot zaviralci PDE

Also Published As

Publication number Publication date
WO2007077490A2 (en) 2007-07-12
TW200736246A (en) 2007-10-01
US20070155779A1 (en) 2007-07-05
CA2636264A1 (en) 2007-07-12
EP1979343A2 (en) 2008-10-15
WO2007077490A3 (en) 2007-10-04
UY30080A1 (es) 2007-08-31
AR058919A1 (es) 2008-03-05
NL2000397A1 (nl) 2007-07-06
NL2000397C2 (nl) 2007-10-30
JP2009522346A (ja) 2009-06-11

Similar Documents

Publication Publication Date Title
PE20071116A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
PE20081151A1 (es) Derivados de imidazol como activadores del receptor de adenosina a2a
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20060302A1 (es) Derivados de benzazepina como antagonistas del receptor h3
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20070750A1 (es) COMPUESTOS DERIVADOS DE 1-AZA-BICICLONONANO COMO LIGANDOS COLINERGICOS DEL RECEPTOR DE ACETILCOLINA NICOTINICA (nAChR)
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
PE20081409A1 (es) Antagonistas del receptor de progesterona
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20081659A1 (es) Agonistas de gpcr
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
GT200600422A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios

Legal Events

Date Code Title Description
FC Refusal